Trial Profile
Efficacy and safety of brentuximab vedotin in patients with relapsed/refractory Hogkin's lymphoma: A retrospective study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Jul 2018
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- 25 Jul 2018 New trial record
- 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association